-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Nektar Therapeutics quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2010 to 2023.
- Nektar Therapeutics Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was -$38K, a 97.9% increase year-over-year.
- Nektar Therapeutics annual Deferred Income Tax Expense (Benefit) for 2023 was -$140K, a 105% decline from 2022.
- Nektar Therapeutics annual Deferred Income Tax Expense (Benefit) for 2022 was $2.71M.
- Nektar Therapeutics annual Deferred Income Tax Expense (Benefit) for 2021 was -$102K, a 183% decline from 2020.
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)